Navigation Links
Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders
Date:1/22/2008

nd Novo A/S (Copenhagen, Denmark). For more information, visit http://www.synosia.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Synosia Therapeutics and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Synosia Therapeutics to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Synosia Therapeutics is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

References

1. Demyttenaere et al. Prevalence, Severity, and unmet needs for treatment of mental disorders in the WHO World Mental Surveys. JAMA (2004) vol. 291 (21) pp. 2581-90.

2. Kessler et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry (2005) vol. 62 (6) pp. 593-602.


'/>"/>
SOURCE Synosia Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Synosia Therapeutics Announces Appointment of Chief Business Officer
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)...   Synthetic Biologics, Inc. (NYSE MKT: ... and drug programs targeting specific pathogens that cause ... the Company,s Investor Day in New ... syndrome (IBS) program, including its novel, oral product ... the keynote presentation, Mark Pimentel , MD, ...
(Date:9/16/2014)... Oro Valley, Arizona (PRWEB) September 16, 2014 ... company that develops safe and effective products to ... through the use of a proprietary SPACEā„¢ Technology ... Executive Officer and President will present at the ... 18, 2014 at the Hyatt Regency Phoenix. ...
(Date:9/16/2014)... , Sept. 16, 2014 /PRNewswire-iReach/ -- Researchers ... (BMSi) test identifies patients with bone fragility fracture ... 160 million people worldwide are at risk of ... today,s standard bone strength test, the DEXA bone ... American Society for Bone and Mineral Research Annual ...
(Date:9/16/2014)... NEW ORLEANS , Sept. 16, 2014 ... Austin, Texas -based cybersecurity company focused on ... 2FA ONE, will support the ability to generate a ... As a pioneer of user-based RFID authentication, ... used for physical access, for many years. RFID authentication ...
Breaking Biology Technology:Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 2Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 3ActiveLife's BMSi Test Provides Hope for 160 Million with Undetectable Risk of Bone Fracture 2ActiveLife's BMSi Test Provides Hope for 160 Million with Undetectable Risk of Bone Fracture 32FA, Inc. Announces RFID-based One-Time Password (OTP) Authentication 2
... Incorporated (Nasdaq: SPEX ), an innovator in ... and providers of technical and regulatory consulting services to ... its President, Dr. Robert Lodder, will be presenting at ... Dr. Lodder will deliver the Company,s corporate presentation ...
... IRVING, Texas, Jan. 5, 2011 Signal Genetics, the ... predictive genetic testing company focused on oncology, and Caris ... enabling precise and personalized healthcare through the highest quality ... announced a new agreement under which Caris Life Sciences ...
... Corporation (Nasdaq: VRNM ), a pioneer in ... today announced that James Levine, Executive Vice President and ... Jaffray Sixth Annual Clean Technology & Renewables Conference.  The ... on Wednesday, January 12, 2011 and will take place ...
Cached Biology Technology:Spherix to Present at Two Upcoming Prominent Finance Conferences 2Spherix to Present at Two Upcoming Prominent Finance Conferences 3Signal Genetics and Caris Life Sciences Announce Commercialization Partnership for New Myeloma Gene Expression Test 2Signal Genetics and Caris Life Sciences Announce Commercialization Partnership for New Myeloma Gene Expression Test 3Verenium to Present at Piper Jaffray Sixth Annual Clean Technology & Renewables Conference 2Verenium to Present at Piper Jaffray Sixth Annual Clean Technology & Renewables Conference 3
(Date:9/15/2014)... both plants and animals alike. , Understanding just how ... to the design of better drugs for diabetes patients ... vegetables farmers are able to grow. Stanford University researchers ... cell by piecing together proteins slightly wider than the ... determine the size, shape and orientation of one of ...
(Date:9/15/2014)... have found "the most famous wheat gene," a reproductive ... transfer valuable genes from other plants to ... develop wheat varieties with the disease- and pest-resistance traits ... that can reduce crop losses and pesticide use while ... Modified Organisms, or GMOs., "The real exciting part of ...
(Date:9/15/2014)... WASHINGTON A new strategic vision document, released ... Research Program, describes the long-term goals, objectives, and ... scope of work over the next five years ... its initial, short-term activities, to be funded in ... and science policy fellowships. , The $500 ...
Breaking Biology News(10 mins):X-rays unlock a protein's SWEET side 2X-rays unlock a protein's SWEET side 3WSU researchers find 'most famous wheat gene' 2NAS Gulf Research Program announces strategic vision, initial opportunities 2NAS Gulf Research Program announces strategic vision, initial opportunities 3NAS Gulf Research Program announces strategic vision, initial opportunities 4
... producing proteins that moonlight, having different roles at different ... killed. The moonlighting activity of one enzyme from the ... of broad-spectrum antibiotics, according to a paper published in ... "Glutamate racemase, or MurI, is an enzyme ...
... many recent reports documenting the therapeutic efficacy of short ... may actually be describing non-specific therapeutic effects related to ... according to a paper in the September 2008 issue ... , a peer-reviewed journal published by Mary Ann Liebert, ...
... NY, Sept. 2, 2008) People concerned about the ... families and communities will have a unique opportunity to ... about the causes, symptoms and progression of such illnesses ... learn about current and potential treatments. In an ...
Cached Biology News:Energy-saving bacteria resist antibiotics 2Previous claims of siRNA therapeutic effects called into question by report in human gene therapy 2Healthy Minds Across America features 48 public forums on mental health research, Sept. 14 2Healthy Minds Across America features 48 public forums on mental health research, Sept. 14 3
Applications: Western blotting ...
...
... efficiencies and the chemistry of light production ... benefit that they require simple triggering conditions ... This benefit has been exploited to great ... compounds can also be easily modified to ...
ssDNA from PCR DNA in less than 1 hour. No gels, columns, or slurries. Sequence from high quality ssDNA: clearer reads, longer runs....
Biology Products: